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DEVELOPMENT OF A LECTIN-FC FUSION PROTEIN WITH ANTIVIRAL AND ANTI-CANCER ACTIVITY 
Matthew William Dent 
February 20, 2019 
This thesis describes the development of a novel lectin-Fc fusion protein and its antiviral 
and anti-cancer activity. The molecule, Avaren-Fc (AvFc), is a fusion of a variant of the 
actinomycete lectin actinohivin (Avaren) and the Fc region of human IgG1, and is selective for 
the terminal α1,2-mannose residues found at the ends of high-mannose-type glycans that can 
be found on the surface of certain heavily glycosylated viruses and cancer cells. Here, AvFc was 
found to be able to neutralize simian immunodeficiency virus as well as Hepatitis C virus with 
nanomolar IC50 values. Furthermore, AvFc recognizes a number of cell surface receptors and is 
capable of protecting mice against lung and flank B16F10 challenges primarily through Fc-
mediated mechanisms. This work builds upon the framework developed by our group 









TABLE OF CONTENTS 
DEDICATION .................................................................................................................................... iii 
ABSTRACT ........................................................................................................................................ iv 
LIST OF FIGURES ............................................................................................................................. vii 
LIST OF TABLES .............................................................................................................................. viii 
CHAPTER I: INTRODUCTION ............................................................................................................. 1 
Glycosylation of Proteins ............................................................................................................. 1 
Description of N-glycans .......................................................................................................... 1 
Aberrant Glycosylation in Cancer and Viruses ......................................................................... 3 
Lectins .......................................................................................................................................... 4 
Antiviral Lectins ........................................................................................................................ 5 
Lectins as Cancer Therapy ........................................................................................................ 7 
Transient Expression and Manufacturing of Biopharmaceuticals in Plants ................................ 8 
Therapy of HIV ........................................................................................................................... 11 
Therapy of Hepatitis C ............................................................................................................... 12 
Avaren-Fc ................................................................................................................................... 13 
CHAPTER II: EXPERIMENTAL PROCEDURES .................................................................................... 18 
Plant Growth .............................................................................................................................. 18 
Expression and Purification of AvFc and Variants ..................................................................... 18 
HIV gp120 ELISA ......................................................................................................................... 20 
Culture of Primary Simian Immunodeficiency Virus (SIV) Strains .............................................. 21 
SIV Titration for Neutralization Assays ...................................................................................... 22 
SIV Neutralization Assay ............................................................................................................ 23 
Flow Cytometry of SIV-Infected Mesenteric Lymph Node Cells ................................................ 24 
Pharmacokinetic Analysis of AvFc in Rhesus Macaques ............................................................ 24 
Production of HCV...................................................................................................................... 25 
TCID50 Assay for HCVcc ............................................................................................................. 26 
HCVcc Neutralization Assay ....................................................................................................... 26 
Flow Cytometry Analysis of AvFc Binding to B16F10 Cells ........................................................ 27 
ADCC Reporter Assay ................................................................................................................. 27
vi 
 
B16F10 Melanoma Lung Metastasis Model .............................................................................. 28 
B16F10 Flank Tumor Model ....................................................................................................... 28 
Proteomic Analysis of AvFc Binding Partners on Cancer Cells ................................................... 29 
MTS Assay .................................................................................................................................. 30 
Scratch Cell Migration Assay ...................................................................................................... 30 
Pharmacokinetics of AvFc in C57bl/6 Mice ................................................................................ 31 
A549-GFP Lung Cancer Model ................................................................................................... 31 
Experimental Animals ................................................................................................................ 31 
CHAPTER III: RESULTS..................................................................................................................... 33 
Anti-SIV Activity of AvFc ............................................................................................................. 33 
Anti-HCV Activity of AvFc ........................................................................................................... 37 
Anti-Cancer Activity of AvFc ....................................................................................................... 38 
CHAPTER IV: DISCUSSION .............................................................................................................. 47 
REFERENCES ................................................................................................................................... 51 
CURRICULUM VITAE ....................................................................................................................... 57 
 
vii 
LIST OF FIGURES 
FIGURE 1 - BASIC STRUCTURES OF THE MAJOR CLASSES OF N-GLYCANS. ...................................................... 3 
FIGURE 2 - YIELD AND GP120 BINDING ACTIVITY OF ACTINOHIVIN VARIANTS. ........................................... 15 
FIGURE 3 - COMPARISON OF ACTINOHIVIN AND AVAREN STRUCTURE BY HOMOLOGY MODELING AND 
CIRCULAR DICHROISM .......................................................................................................................... 15 
FIGURE 4 - GLYCAN ARRAY ANALYSIS AND AFFINITY TO GP120 OF AVFC AND ACTINOHIVIN ...................... 16 
FIGURE 5 - HIV-NEUTRALIZATION ACTIVITY OF AVFC AND ACTINOHIVIN .................................................... 16 
FIGURE 6 - RECOGNITION OF CANCER CELL-LINES AND INDUCTION OF ADCC BY AVFC .............................. 17 
FIGURE 7 - SIV NEUTRALIZATION BY AVFC .................................................................................................... 34 
FIGURE 8 - RECOGNITION OF SIV-INFECTED MACAQUE MLN CELLS BY AVFC .............................................. 35 
FIGURE 9 - MATRIX INTERFERENCE BY MACAQUE SERUM IN THE GP120 ELISA .......................................... 36 
FIGURE 10 - PHARMACOKINETIC ANALYSIS OF AVFC IN RHESUS MACAQUES .............................................. 37 
FIGURE 11 - HCV NEUTRALIZATION BY AVFC ................................................................................................ 38 
FIGURE 12 - BINDING OF AVFC TO B16F10 ................................................................................................... 39 
FIGURE 13 - ADCC ACTIVITY OF AVFC AGAINST B16F10 CELLS ..................................................................... 39 
FIGURE 14 - B16F10 MELANOMA METASTASIS MODEL, CO-TREATMENT WITH AVFC. ............................... 40 
FIGURE 15 - B16F10 MELANOMA METASTASIS MODEL, DELAYED TREATMENT WITH AVFC ....................... 41 
FIGURE 16 - B16F10 FLANK TUMOR MODEL WITH DELAYED TREATMENT................................................... 41 
FIGURE 17 - EFFECT OF AVFC EXPOSURE ON B16F10 VIABILITY ................................................................... 44 
FIGURE 18 - MIGRATION OF AVFC-EXPOSED B16F10 CELLS ......................................................................... 44 
FIGURE 19 - PHARMACOKINETICS OF AVFC IN C57BL/6 MICE ...................................................................... 45 




LIST OF TABLES 
TABLE 1 - IDENTIFICATION OF THE CELL-SURFACE BINDING PARTNERS OF AVFC ........................................ 43 
1 
CHAPTER I: INTRODUCTION 
Glycosylation of Proteins 
The modification of proteins through the addition of oligomeric carbohydrate chains 
(glycosylation) occurs in all domains of life and, in eukaryotes, is central to their processing in 
the endomembrane system. The importance of protein glycosylation is evident in the fact that 
nearly one fifth of all proteins are probably glycosylated [1]. This critical post- and co-
translational modification is necessary for the proper folding and function of proteins that are 
destined for insertion into the plasma membrane or secretion into the extracellular space. The 
enzymes responsible for the addition and modification of the carbohydrate chains, termed 
glycans, are primarily found in the ER and Golgi apparatus. However, cross-species variation in 
the substrate, expression, and localization of these enzymes means that there is an incredible 
diversity in the glycoforms that can be generated. All of these, however, generally fall into one 
of two categories: asparagine (N) linked and serine/threonine (O) linked. While both are 
important to the function and structure of proteins, and although there are other categories of 
glycosylation (including lipid glycosylation), the focus of this section will be on N-linked 
glycosylation. 
 
Description of N-glycans 
The minimal sequence necessary for N-linked glycosylation is NXS/T (sequon), where X is 
any protein that is not proline. The presence of this sequence is not a guarantee that a glycan 
will be attached. In some cases, there are conformational or other constraints that preclude 
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glycosylation. As proteins are fed into the lumen of the ER, an enzyme called 
oligosaccharyltransferase (OST) covalently transfers the precursor glycan from the dolichol-
linked precursor to the first asparagine in the sequon with a β glycosidic bond, which is modified 
enzymatically as the protein makes its way from the ER to the Golgi apparatus [2]. Proper N-
glycosylation is important in signaling to the folding machinery that the protein is in the correct 
conformation and should be processed further, and disruptions in this process lead to protein 
degradation and ER dysregulation/unfolded protein response [3]. While there is a large amount 
of diversity in the resulting glycans, all of them share the same core structure consisting of two 
N-acetylglucosamine residues linked via an β1,4-glycosidic bond to mannose, which is linked to 
two other mannose residues via an α1,3- and an α1,6-bond. The resulting glycans can then be 
divided based on the identity of the residues attached to the core, of which there are three 
types: high-mannose, complex, and hybrid (Figure 1).  
High-mannose glycans (HMGs) contain anywhere from 5 to 9 mannose residues 
(including the core structure) with no further additions to the chain. These are generally 
considered immature glycans, as they are rarely seen on fully processed glycoproteins. Complex 
glycans, conversely, have no mannose residues outside of the core and instead have two or 
more GlcNAc residues that extend from the two mannose arms forming “antennae”. Each of the 
two mannose arms in the core can accommodate the addition of more than two GlcNAc 
residues, resulting in tri- and tetra-antennary structures. In hybrid glycans only the α1,3-linked 
mannose branch of the core is extended by GlcNAc, while the α1,6-linked mannose branch 
remains in the high-mannose form. In addition, many mammalian glycans are modified with a 
core α1,6-fucose residue attached to the proximal GlcNAc residue, though this is not depicted. 
Unique to plants are core α1,3-fucose and β1,2-xylose residues, which connect at the proximal 
GlcNAc and the first mannose residue, respectively. Interestingly, while IgE antibodies against 
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these plant-specific structures have been detected in patients and are cross-reactive with plant 
foods, they have never been shown to induce clinical food allergy [4]. This is important, as they 
are the predominant glycan on proteins produced in plant-based expression systems, and much 
criticism of the system has been levied at the possible allergenicity of these molecules based on 
the unique glycans.  
 
Figure 1 - Basic Structures of the Major Classes of N-Glycans. N-glycans are classified by their 
terminal residues and the number of branches in their structure, as shown above.  
 
Aberrant Glycosylation in Cancer and Viruses 
Changes to the normal pattern of N-glycosylation can be indicative of underlying 
disease, and aberrant glycoforms have been explored for their use as biomarkers and as 
therapeutic targets for cancer and certain viruses. Many glycoproteins belonging to enveloped 
viruses are heavily decorated with N-glycans. This glycosylation serves to both increase the 
affinity of the viral entry proteins to their cognate receptors on the host cell and to mask the 
underlying protein epitopes from the immune system [5]. A common modification is the over-
representation of HMGs, which is seen in Influenza virus, HIV, Hepatitis C virus (HCV), West Nile 
Virus, MERS- and SARS coronavirus (CoV), Ebola virus, and HSV-2 among others [5]. One 
hypothesis is that this is due to changes in the cell metabolism associated with inflammatory 
signaling [6]. It is also possible that high expression of viral proteins produce steric hindrance 
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and prevent the trimming of certain occluded glycans [7]. Though the exact mechanism behind 
why HMGs are found in high quantities on these viruses is unknown, this phenomenon has led 
to the development of glycan-targeting viral entry inhibitors, in particular lectins, as possible 
antiviral therapeutics and prophylactic agents. Lectins are discussed in greater detail in the next 
section. 
Alterations in the glycan profile of glycoproteins and glycosphingolipids are common 
features of cancer cells and are associated with increased cell viability and proliferation, tumor 
cell dissociation, migration, invasion, and modulation of the activity of signal transducers [8]. In 
the case of glycoproteins, the changes in glycosylation are mostly to N- or O-linked glycans. O-
linked glycans are short carbohydrate chains attached to the hydroxyl oxygen of serine or 
threonine residues. Commonly identified changes to the O-glycan profile of cancer cells include 
the increased expression of rare Lewis antigens like sialyl Lewis and LewsiY , Tn and sTn antigens, 
as well as truncated and branched O-glycans [9]. Changes to N-glycans include overexpression of 
core and terminal fucosylation, altered patterns of branching and bisecting GlcNAcs, and HMGs 
[9]. Despite the number of possible glycobiomarkers that have been identified, only a single 
glycan-targeting drug has been approved for use in humans (dinutuximab, which targets GD2 
glycolipids expressed on neuroblastoma cells), necessitating the further development of 
therapies and diagnostics that can target them. 
 
Lectins 
Lectins are a broad class of proteins that recognize and reversibly bind to carbohydrates 
and glycoconjugates – sugar chains that can be found on the surface of other macromolecules 
including other proteins and lipids. In the late 19th century, lectins were very broadly referred to 
as hemagglutinins, or phytoagglutinins, since the erythrocyte agglutinating properties of these 
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proteins were first recognized in plant extracts. The first of these to be isolated from a plant 
extract is arguably the most famous (or infamous): ricin, an incredibly toxic lectin isolated from 
the castor bean (Ricinus communis) by Peter Hermann Stillmark in 1888 at the University of 
Dorpat in what is now Estonia [10]. At the time, lectins were only known as toxins and blood 
agglutinating agents. Studies with the earliest purified lectins, like ricin, abrin, and concanavalin 
A (Con-A) enabled researchers like Paul Ehrlich to determine that the immune system responds 
to individual antigens. Importantly, he determined that mice given sublethal doses of ricin 
eventually became immune to its effect (a discovery that would of course lead to the first 
vaccines). Since then, it has come to be understood that lectins are a very diverse and 
widespread group of proteins, and it is therefore quite difficult to generalize their structures and 
functions. In viruses and bacteria, they appear to play a role in host recognition and infection, 
while in plants they most notably act as defense mechanisms against pathogenic 
microorganisms. In animals and especially humans, lectins play important roles in cell signaling, 
adhesion, and trafficking as well as in immune regulation and pathogen recognition and 
response. This however is oversimplified. Of particular interest are lectins that can specifically 
recognize microbes, as these have tremendous implications for human health and have been 
studied with the intention of possibly developing new classes of therapeutics – the discovery of 
which has been accelerated by new genomics technologies. This section will briefly describe 




A number of lectins have been found to have antiviral activity by targeting glycans found 
on the surface of envelope glycoproteins, which have evolved as both a mechanism to increase 
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viral uptake by increasing affinity to host cell receptors as well as avoid the immune system by 
masking epitopes [11]. Coevolution of lectins with viruses has led to a large repertoire capable 
of recognizing non-self-glycans as a means of innate defense against the pathogens. These 
lectins generally consist of multiple repeated carbohydrate recognition domains (CRD), which 
increases their avidity for branched structures and allows them to more tightly bind to non-self-
proteins. Many of the most well-described lectins in the literature target high-mannose glycan 
(HMG) structures, and consist of multiple CRDs that allow for tight binding to the glycoproteins 
of viruses such as HIV, Ebola virus, SARS-CoV, MERS-CoV, HCV, and many others [12-16]. All of 
these viruses contain heavily glycosylated host-cell-entry proteins that are primarily decorated 
with HMGs, which in normal human cells and glycoproteins are considered to be immature and 
not typically present in large quantities. When HMG-targeting lectins come into contact with 
these proteins and bind, disruption of the tertiary and quaternary structure of the viral 
glycoproteins leads to inhibition of entry and fusion, neutralizing the virus and allowing for 
immune clearance of the pathogens. These lectins are typically broadly active, making them 
attractive for therapeutic development as viral entry inhibitors despite the fact that many are 
toxic at higher doses.  
A number of lectins with antiviral activity targeting HMGs have been isolated from 
bacteria, plants, and marine creatures. Of interest are actinohivin (AH, from actinomycetes), 
cyanovirin-N (CV-N, from a cyanobacterium), Griffithsin (GRFT, from red algae), BanLec (from 
bananas), microvirin (MVN), and scytovirin (from a cyanobacterium) [17-22]. Much work has been 
devoted to developing these as antiviral therapeutic or prophylactic agents and microbicides, 
especially for HIV, though data from in vivo protection models is limited, possibly due to the fact 
that many lectins are cytotoxic or mitogenic at doses that are clinically relevant. Of the lectins 
that have been isolated, GRFT has shown the most promise as an antiviral agent as it is broadly 
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acting and has limited toxicity when administered topically or systemically [23]. It has shown in-
vivo activity against HIV, HSV-2, HCV, Japanese Encephalitis Virus, and SARS-CoV, and has been 
formulated into a rectal microbicide for a first-in-human clinical trial in 2019 (NIH Project Number: 
5U19AI113182-03) [23-27]. CV-N has also shown promise as an anti-HIV agent in macaque SHIV 
challenge models [28, 29], and was well tolerated when administered rectally or vaginally. CV-N 
was formulated into a quick-dissolving vaginal suppository by Osel Inc, which made use of live 
recombinant Lactobacillus jensenii which constitutively expressed CV-N and was capable of 
protecting against SHIV transmission in macaques [30]. Interestingly, CV-N has also shown to have 
activity in a lethal mouse model of Ebola-Z infection [31]. Taken together, these data indicate that 
antiviral lectins may be a viable option for the prevention and treatment of certain viruses and 
that further in vivo studies should be performed. 
 
Lectins as Cancer Therapy 
Aberrant glycosylation has been detected in human cancers, resulting in the increased 
expression of rare antigens or changes in the proportions of others [32]. The utility of lectins as 
neoplastic therapeutic agents has been explored as the discovery of lectins that can bind these 
rare cancer glycoantigens has progressed. However, in general, there is more limited data on 
the in vivo effectiveness of lectins in cancer models. Plant lectins by far have been the most 
studied class of lectin with regards to anti-cancer activity, and several of them are derived from 
plants used in traditional Chinese medicine. Examples of such lectins are Polygonatum odoratum 
lectin (POL), Mistletoe lectin (ML), Con-A, and Soybean lectin. While each of these has shown 
some activity in vitro, the in vivo data is limited [33-40]. For instance, while protection against a 
xenogenic ovarian cancer in SCID mice was noted with ML, it showed no effect in an induced 
mouse bladder cancer model [41, 42]. Further in vivo study is warranted in order to determine 
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whether or not lectins are a viable option as a cancer therapeutic, and work must be done to 
demonstrate the selectivity of these lectins for cancer cells over normal human cells. 
 
Transient Expression and Manufacturing of Biopharmaceuticals in Plants 
Recombinant protein production, whether it be for pharmaceuticals or diagnostic 
reagents, has for the most part taken place in cell-culture-based systems (bacterial, insect, or 
mammalian cells). In these systems, transgenes are introduced to the target cells which mass-
produce the protein of interest, which can then be harvested and purified to a final product. 
However, while considered the standard method of doing so, the time and cost associated with 
this method of production means that they can be difficult to employ in laboratory settings and 
that these drugs are only readily available in the developed world. This has led to the 
development of alternatives that may be more accessible to low-income areas and nations. To 
that end, plant-based expression (often referred to as “molecular pharming”) offers several 
advantages over culture-based methods. Firstly, they are fast and robust, capable of producing 
comparable levels of protein in weeks rather than months [43, 44]. The speed at which new 
proteins can be made also greatly facilitates preclinical development, allowing for rapid testing 
of mutants and product variants. Secondly, they offer an improved safety profile, in that it is 
more unlikely to transfer human infectious material to the final product through soil and plant 
tissue than it is through mammalian cells or a culture medium containing components of animal 
origin. Lastly, they are more cost efficient and require significantly less capital investment for 
large scale production and scale-up [45]. To date, only a single recombinant pharmaceutical 
protein produced in plants has been approved by the FDA. The orphan drug, taliglucerase alfa 
(marketed by Protalix BioTherapeutics and Pfizer as ELELYSO®), is used as an enzyme 
replacement therapy for Gaucher’s Disease and was approved in May 2012 [46]. With other 
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plant-made biopharmaceuticals entering clinical trials and at least one in Phase III (a 
quadrivalent influenza vaccine made by Medicago, see clinical trial record NCT03301051), plants 
are increasingly becoming recognized as a viable option for biopharmaceutical manufacturing.  
The first reports of plant-derived pharmaceuticals were published in the late 80s and 
early 90s and demonstrated the production of immunoglobulins and vaccine antigens in 
transgenic tobacco plants [47, 48]. Much of the early research in molecular pharming then 
focused on the development of edible transgenic crop plants, especially nightshades like potato 
and tomato, for vaccine delivery [49, 50]. The idea at the time was that preparations of edible 
fruits or tubers containing vaccines could be made simply by growing the plant in the field from 
a transgenic seed, and the vaccine could then be given orally as opposed to with an injection. 
Requiring standard agricultural knowledge, rather than having expensive bioreactor facilities, 
meant that the technology to grow and distribute vaccines would be much more readily 
accessible to developing and other low-income countries. In addition, scale-up could easily be 
achieved by simply increasing the growth area. However, there are several caveats to using 
transgenic plants. The first and most problematic of these is that it can be difficult to generate a 
strong enough systemic immune response from orally delivered antigens without an adjuvant. 
The second is that expression levels can be variable from plant to plant even if they are 
genetically identical due to subtle changes in growth conditions, epigenetics, and gene silencing. 
This makes knowing the exact dose contained within the edible portion of the plant difficult and 
may preclude approval by the FDA, which has strict guidelines on vaccine dosing and 
preparation. The third is that transgenic plants can take a long time to make, as several 
generations are needed to transform, select, and then backcross to create the recombinant 
inbred lines that would then be grown on the field. Lastly, and most obviously, is that there is 
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significant public concern around genetically-modified crops which may make it difficult to 
market and sell such a product.  Thus, much research has gone into developing alternatives. 
Transient expression is a more rapid and robust way to produce recombinant protein in 
plants. Unlike with transgenics, transient gene expression constructs are not delivered to 
embryos but rather to fully grown, wild-type plants, the most common being a tobacco relative 
called Nicotiana benthamiana. This method offers many benefits in terms of yield, time, and 
reduced public concern (since food crops are not typically used). Two major types of vector have 
been developed to facilitate transient protein production, based on either full or deconstructed 
plant virus genomes [51]. With full virus-based vectors, the gene of interest (GOI) is inserted into 
a viral genome which then replicates and is translated as the virus spreads through the plant, 
producing the protein in large quantities as it goes. The most well-known example of a full viral 
vector is the GENEWARE® vector, based on tobacco mosaic virus (TMV) [52]. These vectors are 
useful because the virus containing the GOI can be stored in large quantities and can infect new 
plants with little effort, facilitating large scale production. However, infectious viral vectors 
typically cannot produce large-size proteins, as long GOI may prevent efficient viral RNA 
packaging and replication. Deconstructed viral vectors, on the other hand, do not place the GOI 
inside of a replication-competent viral genome. Instead, the major protein-coding genes are 
removed and the GOI is placed under the control of the viral promoter and terminator. Since 
there is no replicating virus with this type of vector, another method of delivery must be used to 
transform the host. This is done by the soil bacterium Agrobacterium tumefaciens, which is well 
known in agriculture as the causative agent of a disease called Crown Gall. The disease is 
characterized by large nodules in roots, branches and twigs, which form after the bacteria 
infects the plant cell and inserts a small piece of DNA (called transfer, or T-DNA, located on the 
tumor-inducing, or Ti, plasmid) into the host genome, which then produces a number of 
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virulence and growth factors for the bacterium [53]. Replacing the tumor-inducing genes on the 
T-DNA with deconstructed viral vector cassettes coding for pharmaceuticals allows for high-level 
production of protein in plants, a process called agroinfiltration. A well-known vector that is 
delivered via this method is magnICON® [54], which is a deconstructed vector based on TMV 
that does not produce replication competent virions. magnICON® has been especially successful 
at expressing therapeutic monoclonal antibodies and vaccines, highlighting the usefulness of 
this system [55-60]. A large number of other deconstructed vectors have been developed for the 
transient expression of recombinant proteins, as recently reviewed by Peyret et al. [51]. 
 
Therapy of HIV 
HIV is a primarily-sexually-transmitted lentivirus that is the causative agent of acquired 
immunodeficiency syndrome, or AIDS, which is responsible for nearly a million deaths 
worldwide every year (WHO). HIV recognizes the CD4 receptor on immune cells, propagating 
inside them and ultimately leading to their death. As CD4+ T cell counts diminish over several 
years to decades, the patient becomes more susceptible to infections and cancer, and will 
eventually succumb as the immune system becomes unable to function. Since the identification 
of the virus in the early 80’s, advancements in antiretroviral therapy (ART) have improved to the 
point where most HIV+ individuals on ART have nearly the same lifespan as people without and 
are less likely to transmit the virus to others. ART is a multi-drug regimen that is initiated at the 
time of diagnosis regardless of the symptoms. The US Department of Health and Human 
Services guidelines suggest that ART begin with 2 nucleoside-analog reverse transcriptase 
inhibitors (NRTIs) delivered with a protease inhibitor, a non-nucleoside reverse transcriptase 
inhibitor (NNRTI), or an integrase inhibitor (INSTI) 
(https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf). The ultimate 
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choice of drug depends on the patient’s baseline resistance to therapy, which should be 
determined prior to the beginning of ART. The downside to ART is its high cost and the potential 
for resistance in the event a patient cannot or does not adhere to their regimen. Thus, there is a 
need to search for other treatment forms that can keep viral loads undetectable while 
improving adherence and lowering the number of adverse events. 
The primary barrier to achieving a cure for HIV is the presence of latently infected 
resting CD4+ memory T cells, which harbor the viral genes but do not actively produce virus [61, 
62]. Upon cessation of ART, these reservoirs can become reactivated and the patient’s viral load 
quickly rebounds. While various cure strategies have been implemented, including bone marrow 
transplant from HIV-resistant donors (as was the case with the Berlin Patient [63]), the focus of 
HIV cure research focuses around the use of latency reversal agents (LRAs) and agents that can 
target and kill reactivated latent cells. Among all of the drugs tested, the histone deacetylase 
inhibitors (HDACis) have shown the most clinical promise in their ability to reactivate latent 
reservoirs in humans, however none have been able to reduce the size of the latent reservoir 
alone [64]. In combination with HDACis, broadly neutralizing antibodies (bNAbs) against HIV 
have been used successfully in animal models to reduce the size of the latent reservoir and 
delay rebound (but not clear it entirely) [65]. This is a major step towards a cure, but more work 
needs to be done to identify LRAs that can more potently reactivate reservoirs and bNAbs that 
can more efficiently target infected cells and elicit antibody-dependent cell-mediated 
cytotoxicity (ADCC). 
 
Therapy of Hepatitis C 
HCV is an enveloped flavivirus that is spread through contaminated blood and causes 
liver damage, inflammation, and eventually cirrhosis and fibrosis. In most people, symptoms do 
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not occur until decades after the initial exposure, by which time liver is already severely 
damaged, and the patient may be in need of a transplant. Prior to 2011, the only treatment 
option for HCV patients was a combination regimen of pegylated interferon and ribavirin, a 
ribonucleoside guanosine analog, which could cure patients approximately 40-80% of the time 
but is also highly toxic with potentially severe side effects [66]. The advent of direct acting 
antivirals (DAAs) has made HCV an all but curable infection, with success rates reaching >90% 
with some genotypes [67]. DAAs inhibit specific parts of the HCV replication cycle primarily by 
targeting the viral protease (simeprevir, telaprevir) and the RNA-dependent RNA polymerase 
(sofosbuvir) [68]. As is the case with HIV, DAA regimens are typically multi-drug combination 
therapies whose composition depends on the genotype and inherent resistance of the strain in 
the patient. Despite the advances in treatment, it is likely that HCV-related liver cirrhosis will be 
the primary reason for liver transplant in the US for years to come. Furthermore, the cost of a 
DAA regimen can be upwards of $100,000 dollars, potentially limiting access to treatment. 
Particularly, in the case of liver transplant, the donor liver is reinfected with HCV almost 
immediately which can lead to accelerated cirrhosis and fibrosis of new organ. Typically, the 
patient cannot receive DAAs until they are off immunosuppressive drugs for a period due to 
potential interactions [69]. Therefore, there may be a need to develop an entry inhibitor that 
can protect donor livers from the virus. 
 
Avaren-Fc 
Previously, our lab has developed a novel fusion protein consisting of a lectin attached 
to the Fc region of human IgG1, called Avaren-Fc (AvFc). The lectin portion, called Avaren, is 
derived from the actinomycete lectin actinohivin, which was identified after screening for novel 
HIV inhibitors [70]. This lectin comprises three homologous tandem sugar-binding domains, 
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each of which being highly specific for the α1,2-linked mannose residues found in HMGs, 
allowing it to effectively neutralize HIV [71]. Unfortunately, when expressed recombinantly in 
plants actinohivin was prone to aggregation and yielded poorly. To increase the yield and the 
viability of actinohivin as a potential new drug, a number of mutations were made to neutralize 
the surface charge variation and decrease the propensity for aggregation (manuscript in 
preparation). Variant 8, which gave the highest yield while maintaining gp120-binding activity, 
was renamed Avaren (actinohivin variant expressed in Nicotiana, Figure 2). Furthermore, Avaren 
displayed similar overall structure as determined by circular dichroism and homology modeling 
(Figure 3). Avaren was then fused to the Fc portion of human IgG1 to further improve its activity 
by dimerization. The resulting protein, AvFc, retained the binding specificity of the original 
molecule while improving its affinity for gp120 (Figure 4) as well as its HIV neutralization activity 
(Figure 5). Additionally, the addition of the Fc region adds the possibility that AvFc can elicit 
antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity 
(CDC) as well as have an antibody-like half-life by binding to the neonatal Fc receptor (FcRn). 
Induction of ADCC is particularly important in cancer therapy, making up an important part of a 
therapeutic mAb’s mechanism of action (MOA) and improving its overall activity. As shown in 
Figure 6, AvFc can effectively bind to a number of different cancer cell-lines in a dose-dependent 
manner, with saturation occurring around 130 nM for most lines tested. Additionally, it can also 
elicit a stronger ADCC response against A549, MCF7, and RKO cells than can the approved 
therapeutic mAbs cetuximab and trastuzumab. This makes AvFc a novel first-in-class HMG-
binding agent that combines both sugar recognition and Fc functions, justifying further study 







Figure 2 - Yield and gp120 binding activity of actinohivin variants. Mutations were made in 
each of the three sugar-binding domains to decrease the overall hydrophobicity of the molecule 
and improve its production capability. Variant 8 gave the highest yield in a transient plant 
expression system while maintaining gp120-binding activity. This variant was renamed Avaren. 
 
 
Figure 3 - Comparison of actinohivin and Avaren structure by homology modeling and circular 
dichroism. In the left panel, homology modeling shows that the predicted Avaren structure 
closely superimposes over the known crystal structure of actinohivin. In the right, circular 
dichroism analysis suggests that there is a mild increase in random coil structures. Nonetheless, 
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Actinohivin 1 ASVTIRNAQTGRLLDSNYNGNVYTLPANGGNYQRWTGP 38 
39 GDGTVRNAQTGRCLDSNYDGAVYTLPCNGGSYQKWLFY 76 
77 SNGYIQNVETGRVLDSNYNGNVYTLPANGGNYQKWYTG 114 
 
Variant 1  1 ASGTIRNAETGRLLDSNYDGAVYTLPANGGSYQRWTGP 38 
39 GDGTVRNAETGRLLDSNYDGAVYTLPANGGSYQKWTGP 76 
77 GDGTIQNAETGRLLDSNYDGAVYTLPANGGSYQKW-TG 114 
 
Variant 2  1 ASGTIRNAETGRCLDSNYDGAVYTLPCNGGSYQRWTGP 38 
39 GDGTVRNAETGRCLDSNYDGAVYTLPCNGGSYQKWTGP 76 
77 GDGTIQNAETGRCLDSNYDGAVYTLPCNGGSYQKW-TG 114 
 
Variant 3 1 ASVTIRNAETGRLLDSNYNGNVYTLPANGGNYQRWTGP 38 
39 GDGTVRNAETGRCLDSNYDGAVYTLPCNGGSYQKWLFY 76 
77 SNGYIQNVETGRVLDSNYNGNVYTLPANGGNYQKWYTG 114 
 
Variant 4  1 ASVTIRNAETGRCLDSNYNGNVYTLPCNGGNYQRWTGP 38 
39 GDGTVRNAETGRCLDSNYDGAVYTLPCNGGSYQKWLFY 76 
77 SNGYIQNVETGRCLDSNYNGNVYTLPCNGGNYQKWYTG 114 
 
Variant 5  1 ASGTIRNAETGRLLDSNYNGNVYTLPANGGNYQRWTGP 38 
39 GDGTVRNAETGRCLDSNYDGAVYTLPCNGGSYQKWTGP 76 
77 GDGTIQNAETGRVLDSNYNGNVYTLPANGGNYQKW-TG 114 
 
Variant 6  1 ASGTIRNAETGRCLDSNYDGNVYTLPCNGGSYQRWTGP 38 
39 GDGTVRNAETGRCLDSNYDGNVYTLPCNGGSYQKWTGP 76 
77 GDGTIQNAETGRCLDSNYDGNVYTLPCNGGSYQKW-TG 114 
 
Variant 7  1 ASGTIRNAQTGRCLDSNYNGNVYTLPCNGGNYQRWTGP 38 
39 GDGTVRNAQTGRCLDSNYDGAVYTLPCNGGSYQKWTGP 76 
77 GDGTIQNAETGRCLDSNYNGNVYTLPCNGGNYQKW-TG 114 
 
Variant 8  1 ASGTIRNAETGRCLDSNYNGNVYTLPCNGGNYQRWTGP 38 
39 GDGTVRNAETGRCLDSNYDGAVYTLPCNGGSYQKWTGP 76 
77 GDGTIQNAETGRCLDSNYNGNVYTLPCNGGNYQKW-TG 114 
 
Variant 9  1 ASGTIRNAQTGRCLDSNYNGNVYTLPCNGGNYQRWTGP 38 
39 GDGTVRNAETGRCLDSNYDGAVYTLPCNGGSYQKWTGP 76 
77 GDGTIQNAETGRCLDSNYNGNVYTLPCNGGNYQKW-TG 114 
 
Variant 10 1 ASGTIRNAETGRCLDSNYNGNVYTLPCNGGNYQRWTGP 38 
39 GDGTVRNAQTGRCLDSNYDGAVYTLPCNGGSYQKWTGP 76 
77 GDGTIQNAETGRCLDSNYNGNVYTLPCNGGNYQKW-TG 114 
 
Variant 11 1 ASGTIRNAQTGRLLDSNYNGNVYTLPANGGNYQRWTGP 38 
39 GDGTVRNAQTGRLLDSNYNGNVYTLPANGGNYQKWTGP 76 
77 GDGTIQNAQTGRVLDSNYNGNVYTLPANGGNYQKW-TG 114 
Actinohivin 1 ASVTIRNAQTGRLLDSNYNGNVYTLPANGGNYQRWTGP 38 
39 GDGTVRNAQTGRCLDSNYDGAVYTLPCNGGSYQKWLFY 76 
77 SNGYIQNVETGRVLDSNYNGNVYTLPANGGNYQKWYTG 114 
 
Variant 1  1 ASGTIRNAETGRLLDSNYDGAVYTLPANGGSYQRWTGP 38 
39 GDGTVRNAETGRLLDSNYDGAVYTLPANGGSYQKWTGP 76 
77 GDGTIQNAETGRLLDSNYDGAVYTLPANGGSYQKW-TG 114 
 
Variant 2  1 ASGTIRNAETGRCLDSNYDGAVYTLPCNGGSYQRWTGP 38 
39 GDGTVRNAETGRCLDSNYDGAVYTLPCNGGSYQKWTGP 76 
77 GDGTIQNAETGRCLDSNYDGAVYTLPCNGGSYQKW-TG 114 
 
Variant 3  1 ASVTIRNAETGRLLDSNYNGNVYTLPANGGNYQRWTGP 38 
39 GDGTVRNAETGRCLDSNYDGAVYTLPCNGGSYQKWLFY 76 
77 SNGYIQNVETGRVLDSNYNGNVYTLPANGGNYQKWYTG 114 
 
Variant 4  1 ASVTIRNAETGRCLDSNYNGNVYTLPCNGGNYQRWTGP 38 
39 GDGTVRNAETGRCLDSNYDGAVYTLPCNGGSYQKWLFY 76 
77 SNGYIQNVETGRCLDSNYNGNVYTLPCNGGNYQKWYTG 114 
 
Variant 5  1 ASGTIRNAETGRLLDSNYNGNVYTLPANGGNYQRWTGP 38 
39 GDGTVRNAETGRCLDSNYDGAVYTLPCNGGSYQKWTGP 76 
77 GDGTIQNAETGRVLDSNYNGNVYTLPANGGNYQKW-TG 114 
 
Variant 6  1 ASGTIRNAETGRCLDSNYDGNVYTLPCNGGSYQRWTGP 38 
39 GDGTVRNAETGRCLDSNYDGNVYTLPCNGGSYQKWTGP 76 
77 GDGTIQNAETGRCLDSNYDGNVYTLPCNGGSYQKW-TG 114 
 
Variant 7  1 ASGTIRNAQTGRCLDSNYNGNVYTLPCNGGNYQRWTGP 38 
39 GDGTVRNAQTGRCLDSNYDGAVYTLPCNGGSYQKWTGP 76 
77 GDGTIQNAETGRCLDSNYNGNVYTLPCNGGNYQKW-TG 114 
 
Variant 8  1 ASGTIRNAETGRCLDSNYNGNVYTLPCNGGNYQRWTGP 38 
39 GDGTVRNAETGRCLDSNYDGAVYTLPCNGGSYQKWTGP 76 
77 GDGTIQNAETGRCLDSNYNGNVYTLPCNGGNYQKW-TG 114 
 
Variant 9  1 ASGTIRNAQTGRCLDSNYNGNVYTLPCNGGNYQRWTGP 38 
39 GDGTVRNAETGRCLDSNYDGAVYTLPCNGGSYQKWTGP 76 
77 GDGTIQNAETGRCLDSNYNGNVYTLPCNGGNYQKW-TG 114 
 
Variant 10 1 ASGTIRNAETGRCLDSNYNGNVYTLPCNGGNYQRWTGP 38 
39 GDGTVRNAQTGRCLDSNYDGAVYTLPCNGGSYQKWTGP 76 
77 GDGTIQNAETGRCLDSNYNGNVYTLPCNGGNYQKW-TG 114 
 
Variant 11 1 ASGTIRNAQTGRLLDSNYNGNVYTLPANGGNYQRWTGP 38 
39 GDGTVRNAQTGRLLDSNYNGNVYTLPANGGNYQKWTGP 76 


































































Figure 4 - Glycan array analysis and affinity to gp120 of AvFc and actinohivin. In the left panel, 
a glycan array analysis indicates that AvFc has similar specificity for HMGs, and that modification 
of the protein to Avaren did not alter the glycan-binding profile. In the right panel, modification 
to Avaren and dimerization through fusion to the Fc region of IgG1 improved the affinity of the 
molecule to HIV gp120 8-fold, from 29.1 nM to 3.54 nM.  
 
 
Figure 5 - HIV-neutralization activity of AvFc and actinohivin. The ability of AvFc and actinohivin 
to neutralize HIV was tested in a primary-cell-based neutralization assay. AvFc was capable of 
neutralizing multiple group M strains of HIV as well as group O and HIV-2, with an average IC50 




































































































KD = 29.1 ± 0.06 nM; n = 2 KD = 3.54 ± 0.01 nM; n = 2
























































































































Figure 6 - Recognition of cancer cell-lines and induction of ADCC by AvFc. The left panel shows 
the binding of AvFc to a number of different cancer cell-lines originating from a variety of 
tissues. For most cell-lines shown, binding occurs in a dose dependent manner with saturation 
generally occurring around 10 μg/mL, or ≈ 130 nM. The right panel shows that AvFc effectively 
induces ADCC in a luciferase-expressing reporter-cell-based assay against three cancer cell-lines: 
A549, MCF7, and RKO. Furthermore, AvFc elicits a stronger response than the approved 
therapeutic mAbs cetuximab and trastuzumab.  
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CHAPTER II: EXPERIMENTAL PROCEDURES 
Plant Growth  
N. benthamiana was grown in a temperature-controlled room kept at a low humidity, 
with fluorescent lighting timed to a 16/8 hour day/night cycle. Seeding was done in new pots 
containing damp Jiffy Coco Mix, with 3-5 seeds per pot. Following seeding, plants were 
fertilized, covered with plastic wrap and incubated for 12 days, after which they were thinned 
and separated to a lower growth density. Fertilization and watering continued every other day 
until 4 weeks of age, at which point plants were ready for agroinfiltration. 
 
Expression and Purification of AvFc and Variants 
AvFc and variants were expressed in N. benthamiana using the MagnICON® vector 
system, which consists of three modules contained in separate plasmids: a 5’ module, an 
integrase module, and a 3’ module containing the gene of interest. Each plasmid was 
transformed into A. tumefaciens GV3101 by electroporation, and selection was performed using 
YenB agar (1% nutrient broth, 0.5% yeast extract) containing rifampicin (50 μg/mL) and 
ampicillin (100 μg/mL). A separate liquid culture made up of YenB, rifampicin, and ampicillin was 
then made for each of the three transformed cell lines and grown overnight at 30°C. When the 
cultures reached an OD600 of at least 1.0, they were spun down and resuspended in a small 
amount of MES buffer (10 mM MES, 10 mM MgSO4 pH 5.5), and the OD600 remeasured. Each cell 
line was then mixed into a larger MES solution at a final OD600 of 0.03. This solution was then 
used for vacuum infiltration of the plants, which was done by submerging the plant upside down 
19 
into the solution inside a vacuum chamber and sealing it. A pump was used to create the 
vacuum, to which the plant and solution was exposed to for 3 minutes. Afterwards, the pressure 
was relieved slowly, at which point the bacteria solution infiltrated the leaf tissue. This 
procedure was repeated for each plant. After infiltration, plants were returned to the growth 
chamber and incubated for 7 days. 
At 7 days post infiltration (dpi), leaf tissue was harvested from the plants and 
homogenized using a Waring blender with extraction buffer (20 mM NaPi, 40 mM Ascorbic acid, 
pH 7). This crude extract was filtered through a layer of cheesecloth and miracloth, and the 
filtrate was centrifuged at 15,000 xg for 15 minutes at 4°C. Concentrated HCl was used to lower 
the pH of the supernatant to 5.2, which was spun again at 15,000 xg for 10 minutes at 4°C. Then, 
the pH of the supernatant was rapidly brought back to pH 7 and spun again at 15,000 xg for 10 
minutes at 4°C. This clarified extract was then filtered with a 0.2 μm vacuum filter for 
purification by Fast Protein Liquid Chromatography (FPLC). 
FPLC was performed using the AKTA Pure system (GE Healthcare Life Sciences) and a 
two-step purification procedure. The first step was affinity chromatography using a prepacked 5 
mL Protein A column (HiTrap® MabSelect™ SuRe™, GE Healthcare Life Sciences #GE11-0034-94). 
For murine AvFc IgG1, a Protein G column (HiTrap Protein G HP, GE Healthcare Life Sciences 
#17040501) was used instead of Protein A, as murine IgG1 does not bind to it. However, the 
protocol for both is the same. First, the column was equilibrated with 5 column volumes (CV) of 
extraction buffer. Clarified plant extract was then loaded onto the column at 2.5 mL/min, giving 
a residence time of 2 minutes. After sample loading, the column was washed with 10 CV of 
Protein A wash buffer (5 mM NaPi, pH 7) and then eluted with 10 CV of Protein A elution buffer 
(2 M arginine, pH 3) into 5 mL fractions. Fractions containing the protein (typically 2-5) were 
neutralized with 1 M tris and then pooled together for further purification. 
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The second round of purification was performed with a 5 mL prepacked ceramic 
hydroxyapatite column (Bio-Scale Mini CHT Type II 40 μm, Bio-Rad #7324334). Pooled fractions 
from the previous step were diluted with water until the conductivity of the solution dropped 
below ≤ 10 mS/cm. Then, the CHT column was neutralized with 1 CV of a neutralization buffer 
(250 mM NaPi pH 7) and equilibrated with 10 CV of CHT wash buffer (5 mM NaPi pH 7). Sample 
was loaded at a rate of 2.5 mL/min giving a 2 min residence time, after which the column was 
washed with 5 CV of CHT wash buffer. Protein was eluted from the column using a linear step 
from 0% to 100% CHT elution buffer (5 mM NaPi pH 7, 800 mM NaCl) over 10 CV. The elutions 
were collected as 10 mL fractions. Finally, the column was stripped with CHT stripping buffer (5 
mM NaPi pH 7, 4 M NaCl). Fractions were analyzed by SDS-PAGE, and protein-containing 
fractions were pooled and concentrated on a 10 kDa MWCO Amicon® filter (Millipore #C7715). 
The same filters were also used to exchange the buffer for the final AvFc formulation buffer (30 
mM histidine, 100 mM sucrose, 100 mM NaCl, pH 7.4). Endotoxin was removed from the final 
purified product using phase separation with Triton X-114. Briefly, 1% Triton X-114 was added to 
the protein, which was then heated to 37°C and spun in a centrifuge. The uppermost aqueous 
layer was taken, and endotoxin removal was confirmed using the Limulus Amebocyte Lysate test 
(Charles River Endosafe®-PTS). Final product had an endotoxin level of <1 units/mg of AvFc and 
was stored in aliquots at -80°C. 
 
HIV gp120 ELISA 
Clear 96-well plates were coated with 0.3 μg/mL of HIV gp120 CM235 (NIH Aids Reagent 
Program #2968) in carbonate buffer pH 9.6 and incubated overnight at 4°C. Plates were then 
blocked with PBST containing 5% dry milk for 30 minutes at 37°C. AvFc or other variants were 
then added to the plate at 13 nM (1 μg/mL) and serially diluted down the plate 1:5, then 
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incubated for 1 hour at 37°C. AvFc was then detected with a goat anti-human IgG HRP (Santa 
Cruz Biotechnology #2907) at a dilution of 1:10,000 for 1 hour at 37°C. Between each step, 
plates were washed with PBST 3 times. After a final washing, plates were incubated for no more 
than 4 minutes with TMB substrate (Seracare #5120-0075). At that time, the reaction was 
stopped with a solution of 0.6 N sulfuric acid and 1 N HCl and read on a BioTek plate reader at 
450 nm. Absorbance at 450 nm was plotted against the log of the concentration and fit with a 4-
parameter non-linear regression with GraphPad Prism to calculate EC50. The lower limit of 
detection (LLOD) and lower limit of quantification (LLOQ) were calculated as the background 
signal plus 3 times the standard deviation of the background or 10 times the standard deviation, 
respectively, and interpolated using the non-linear regression. 
 
Culture of Primary Simian Immunodeficiency Virus (SIV) Strains 
SIV [what strains?] was propagated in CEMx174 suspension cells (NIH Aids Reagent 
Program #272), which is a fusion cell line formed from the human T cell line CEM and the human 
B cell line 721.174 that is commonly used for propagation of SIV, SHIV, and HIV [need citations]. 
These cells are cultured in RPMI 1640 supplemented with 10% FBS to a density of approximately 
1-2 x 106 cells/mL. For infection, approximately 5 x 106 cells were pelleted, resuspended in 1 mL 
of the virus (pulled from frozen storage), then incubated at 37°C for 1 hour. Some cells were also 
set aside to remain uninfected for future use. Afterwards, cells were diluted in growth medium 
and incubated at 37°C with 5% CO2. Each day, cell cultures were monitored for growth and virus-
induced cytotoxicity and beginning on day 3, cultures were assayed for the presence of the SIV 
capsid protein p27 using a commercial ELISA kit (XpressBio #SK845). Uninfected cells were fed to 
the virus cultures if a slowdown in growth or virus production was noted, and upon confluency 
cells were split into new flasks by dilution with fresh medium to keep propagating virus. When 
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the concentration of p27 was ≥ 100 ng/mL, cell-free virus stocks were made by spinning down 
cells at 1000 xg for 5 minutes, collecting the supernatant, and storing in 1 mL internally-
threaded cryovials at -80°C.  
 
SIV Titration for Neutralization Assays 
To determine the amount of virus needed for the SIV neutralization assay, a titration 
assay with TZM-bl cells as the host was used. TZM-bl is a recombinant Hela cell line that 
expresses CD4 and CCR5 and contains a Tat-activated luciferase gene, making it useful to 
monitor HIV or SIV infection [72]. To a white 96 well plate, 50 μL of TZM-bl growth medium 
(Dulbecco’s Modified Eagle Medium, DMEM, supplemented with 10% FBS) was added to each 
well in columns 2-12, leaving column 1 empty. Then, 62.5 μL of neat virus was added to at least 
4 wells in column 1. This allows for the testing of two viruses per plate. Virus was serially diluted 
1:5 across the plate from column 1 to 11 by transferring 12.5 μL between wells and discarding 
12.5 μL from the last column. Then, 150 μL of TZM-bl cells at a concentration of 6.7 x 104 
cells/mL in growth medium were added to each well on the plate (10,000 cells/well) and 
incubated for 2 days at 37°C with 5% CO2. After this incubation period, plates were removed 
from the incubator and 100 μL of medium was removed from each well. To each well, 100 μL of 
luciferase reagent (BriteLite Plus Reporter Gene Assay System, Perkin Elmer #6066761) was then 
added and incubated for 1 minute, after which plates were read on a BioTek plate reader. The 
viral titer (TCID50) was calculated using the Reed and Muench method [73]. A relative 
luminescence (RLU) value greater than 2.5x the cell-only control value was considered positive 
for infection. In addition, a dilution of virus that would give an RLU value of at least 10x greater 
than the cell only control was chosen for use in the neutralization assay. 
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SIV Neutralization Assay 
The SIV neutralization assay was carried out on a white opaque 96-well plate with TZM-
bl cells as the host cell. This format allows for the testing of three samples with 8 dilutions and 
includes no-drug, no-drug/virus, and no-drug/virus/cell control columns. To begin, 50 μL of TZM-
bl growth medium was added to Rows B-H in columns 1-9. 50 μL of medium was also added to 
column 10 (for the no-drug control), 100 μL to column 11 (for the no-virus control), and 200 μL 
to column 12 (blank). AvFc was prepared in growth medium at 4x the desired starting 
concentration and 62.5 μL of drug was added to at least 3 wells in row A for triplicate analysis. 
As a negative control, the control lectibody AvFclec-, which contains mutations in the Avaren 
portion of the protein that eliminates sugar-binding (Y32A, Y70A, Y108A), was prepared and 
plated in a similar manner. Each drug was serially diluted 1:5 down the plate from Row A to H by 
transferring 12.5 μL between wells and discarding 12.5 μL from the last dilution. SIV, either 
smE660, mac239, or mac251 strain was diluted in growth medium to a dilution 4x higher than 
the desired dilution. 50 μL of virus was then added to each well in columns 1-10. The plate was 
incubated for 1 hour at 37°C and 5% CO2. After this incubation step, TZM-bl cells are harvested 
and resuspended to a concentration of 1 x 105 cells/mL in growth medium. 100 μL of these cells 
are then added to every well in columns 1-11 (10,000 cells/well) and the plates are incubated 
for 2 days at 37°C with 5% CO2. After two days, 100 μL of medium is removed from each well 
and 100 μL of luciferase reagent is added to each well, then the plate is read on a BioTek plate 
reader. Inhibition was counted as a decrease in RLU. The average RLU value of the no-drug/virus 
controls were subtracted from each well as background. Sample RLU values were then 
converted to percent inhibition using the following formula: 





Percent inhibition vs. sample concentration was then plotted with GraphPad Prism. The 
50% inhibitory concentrations (IC50s) for each sample were calculated using a 4-parameter non-
linear regression analysis. 
 
Flow Cytometry of SIV-Infected Mesenteric Lymph Node Cells 
Cells isolated from rhesus macaque mesenteric lymph nodes (MLNs) were infected with 
SIVmac251 and cultured in RPMI 1640 supplemented with 10% FBS and 40 U/mL of human IL-2 
(Tonbo Biosciences #21-8029). Uninfected cells were also cultured as a control. Cultures were 
monitored for p27 expression using a commercial ELISA kit as described above. After infection 
was confirmed by a positive ELISA test, cells were harvested and blocked with a solution of 
PBST, 3% BSA, and human Fc block (BD #564219) for 30 minutes on ice. Cells were then washed 
and stained with 1 or 10 μg/mL AvFc and then with a goat anti-human IgG-FITC secondary 
(Abcam #ab97224). Flow cytometry was performed on a BD FACScan. Cell populations were 
gated for live lymphocytes and unstained cells were used to determine the background 
fluorescence.  
 
Pharmacokinetic Analysis of AvFc in Rhesus Macaques 
Two adult female rhesus macaques (RYL15 and RBL15), weighing 5.76 and 5.72 kg, were 
given a 21 mg bolus intravenous injection of AvFc equaling a dose of 3.6 and 3.7 mg/kg. Blood 
was sampled at 0, 0.5, 1, 2, 4, 8, 24, 48, and 72 hours and placed in serum tubes containing 
EDTA. Serum was then separated from whole blood through centrifugation and assayed for AvFc 
with a gp120 ELISA. To determine whether or not there was any matrix interference, a standard 
gp120 ELISA was performed as described above by spiking varying concentrations of normal 
macaque serum (Innovative Research #IRS-SER) with AvFc and assessing any change in EC50, 
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LLOD, or LLOQ using GraphPad Prism. Once any interference was established, gp120 ELISA with 
purified AvFc as a standard was used to extrapolate the concentration of drug in the PK samples. 
The concentration of AvFc in the serum was plotted against time and PK parameters estimated 
using PK Solver [74]. 
 
Production of HCV  
Cell culture HCV (HCVcc) can be produced by transfecting Huh7.5 cells with RNA coding 
for the viral genes. The DNA construct containing the sequence for the J6/JFH fusion virus 
(genotype 2a) and the Huh7.5 cell line was obtained from Apath, LLC. All washing and 
centrifugation steps take place at 4°C, and materials are kept on ice unless otherwise specified. 
Huh7.5 cells were first grown in a large flask to 90% confluency in DMEM supplemented with 
10% FBS, after which they were washed with PBS, trypsinized, and resuspended in 10-15 mL of 
ice-cold RNase-free PBS. At this point, the cells were counted and washed two more times with 
RNase-free PBS. For the last wash, cells were resuspended in RNase-free PBS to a final 
concentration of 1.5 x 107 cells/mL. At the same time, viral RNA was generated from the DNA 
construct using the mMessage mMachine T7 RNA transcription kit (ThermoFisher #AM1344). 1 
to 10 μg of the RNA was then placed in an RNA-free 1.5 mL tube and mixed with 0.4 mL of the 
cell suspension. This mixture was transferred to a 4 mm cuvette and electroporated at 270 V 
and a capacitance of 950 μF and then left at room temperature for 10 minutes. Afterwards, the 
transformed cells were transferred to a 75 cm2 flask containing 11.6 mL of growth medium and 
incubated at 37°C and 5% CO2 until they became > 85% confluent. At this point the medium was 




TCID50 Assay for HCVcc 
The viral titer was determined using an immunofluorescence assay. Black 96-well plates 
were seeded with 5000 cells/well and incubated overnight to allow their attachment. The next 
day, serial dilutions (1:10) of virus beginning from neat virus were added to the wells, and the 
plates were incubated for 72 hours at 37°C with 5% CO2. After this incubation period, the 
medium was aspirated and disposed of, and the cells were fixed and permeabilized using an ice-
cold 1:1 solution of methanol and acetone. The solution and cells were allowed to equilibrate to 
room temperature for 10 to 20 minutes, after which they were washed twice with PBS. 
Immunostaining was done with an anti-HCV core antigen FITC conjugate monoclonal antibody 
(Abcam ab123076) at a 1:1000 dilution in 3% BSA/PBS for 2 hours at room temperature. The 
cells were then washed and stained with DAPI (Abcam ab228549) for 10 minutes at 4°C. Lastly, 
the infected cells were visualized using a fluorescence microscope. The number of foci in each 
well was counted to determine the endpoint titer and the TCID50 was calculated using the Reed 
and Muench method [73]. 
 
HCVcc Neutralization Assay 
The HCV neutralization assay was carried out using an immunofluorescence assay on a 
96-well plate. First, the plate was seeded with 5000 cells/well and incubated overnight. The next 
day, cells were washed and AvFc was added in 100 μL of growth medium to the plate in 1:5 
serial dilutions beginning at 2x the desired starting concentration (130 nM). One column of wells 
was left with no drug to serve as a positive control. After, HCVcc was added to each well at a 
multiplicity of infection (MOI) of 0.1, and the plates were incubated for 72 hours at 37°C with 5% 
CO2. At that time, the cells were fixed and stained as described above, and the number of 
infected cell foci (foci forming units, FFU) per well were counted. Inhibition was counted as a 
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reduction in FFU. The counts were then converted to percent inhibition using the following 
formula: 




Percent inhibition vs. sample concentration was then plotted with GraphPad Prism. The 
50% inhibitory concentrations (IC50s) for each sample were calculated using a 4-parameter non-
linear regression analysis. 
 
Flow Cytometry Analysis of AvFc Binding to B16F10 Cells 
B16F10 cells were grown in DMEM supplemented with 10% FBS. For flow cytometric 
analysis, cells were harvested with a 0.25% trypsin/EDTA solution and washed with PBS. Cells 
were then stained with a PBS control, AvFc at 1.3, 13, or 130 nM or AvFclec- at 130 nM, and a 
goat anti-human Fc-FITC at 1:250. All incubations were carried out on ice for half an hour in the 
dark. Cells were the analyzed using a BD FACScan and the FlowJo software. Live cells and cells 
positive for FITC were gated based on the PBS control, and the results were analyzed in 
GraphPad Prism. 
 
ADCC Reporter Assay 
The ADCC assay was carried out using the Promega ADCC Bioassay Effector Cells, 
Propagation Model (Promega #G7102). For the assay, the B16F10 target cells were grown as 
described above. At the same time the effector cell line, Jurkat-FcγRIIIa-luc, was grown in RPMI 
1640 supplemented with 10% FBS, 100 μg/mL hygromycin, 250 μg/mL antibiotic G-418 sulfur 
solution, 1 mM sodium pyruvate, and 0.1 mM MEM non-essential amino acids. On a 96-well 
plate, 10,000 B16F10 cells were plated per well and allowed to adhere overnight. The next day, 
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dilutions of AvFc were prepared on a separate plate and added on top of the cells in addition to 
150,000 effector cells. The plates were incubated overnight at 37°C, after which the cells were 
lysed. Lysate was mixed with luciferase assay reagent (Promega #E1500) and luminescence read 
on a plate reader. RLU values from the plate reader were converted to fold induction based on 
the background signal, plotted against the concentration, and fit with a non-linear regression 
using GraphPad Prism. 
 
B16F10 Melanoma Lung Metastasis Model 
For the mouse model of melanoma lung metastasis only 8-10-week-old C57bl/6 mice 
were used, and B16F10 cells were grown as described above. On day 0, animals received their 
first intraperitoneal dose of either vehicle (n=40), 25 mg/kg AvFc (n=30), or 25 mg/kg AvFclec- 
(n=10). 2-4 hours later, 2.5 x 105 B16F10 cells were injected intravenously into each animal. 
Dosing continued every other day for a total of 6 doses. On day 21 animals were euthanized and 
their lungs were removed for analysis. For each lung, the number of black tumor nodules was 
noted. The same model was also used with a delayed treatment of AvFc or vehicle (n=10 each), 
which began on day 7 and continued every other day for a total 6 doses. Animals were 
monitored until their death or until their condition necessitated euthanasia. 
 
B16F10 Flank Tumor Model 
In this model, 20 8-10-week-old C57bl/6 mice were shaved and given 2.5 x 105 B16F10 
cells in the hind left flank. Treatment with AvFc intraperitoneally at 25 mg/kg or vehicle began 
when the tumors became visible (approximately 50 mm3), at 5 days post injection. The size of 
the tumor was measured each day with digital calipers, and animals were euthanized when the 
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tumor size reached 1500 mm3. Dosing continued every other day until study termination at day 
14.  
 
Proteomic Analysis of AvFc Binding Partners on Cancer Cells 
Co-immunoprecipitation was used to isolate potential binding partners of AvFc on the 
surface of cancer cells. Four different cancer cell lines were chosen for analysis, representing 
two lung cancers (H460 and A549) and two blood cancers (HL-60 and K562). The two lung cancer 
cell lines were grown using DMEM supplemented with 10% FBS, while the blood cancer cell lines 
were grown in suspension with RPMI 1640, supplemented with 10% FBS. Co-
immunoprecipitation was performed using the Pierce™ Co-Immunoprecipitation Kit 
(ThermoFisher #26149) according to the kit instructions. Briefly, AvFc or AvFclec- was covalently 
linked to an agarose resin. Then, 1 x 107 cells were lysed using a buffer containing 1% NP-40 and 
1X Halt™ protease and phosphatase inhibitor (ThermoFisher # 78430) and centrifuged to 
separate debris from the lysate. The lysate was first pre-cleared with unconjugated agarose 
resin to remove any proteins that may bind non-specifically to the resin. It was then incubated 
with the conjugated resins for 2 hours at 4°C, after which the spin-tubes containing the mixture 
were placed in a spin column and washed 5 times. Proteins bound to AvFc were eluted from the 
column using a low pH buffer. Several elutions were performed, and each fraction was pooled 
together and neutralized with 1 M tris. To identify the proteins that had bound to AvFc, the 
solution was submitted for proteomic analysis by Liquid Chromatography-Mass Spectrometry at 
the University of Louisville Proteomics Core. The Scaffold Viewer proteomic software with Gene 
Ontology (GO) was used to analyze the LC-MS data. Proteins identified in the AvFclec- sample 
were discarded from the analysis. Additionally, GO keywords were used to trim the dataset to 




B16F10 cells were grown as described above. 5,000 cells were plated into each well of a 
96-well plate. Cells were then exposed to AvFc or AvFclec- beginning at 3 μM with 1:5 serial 
dilutions. Multiple wells were left for use as a no-drug control. Plates were incubated for 48 
hours at 37°C, at which point 20 μL of MTS reagent was added to each well (Abcam ab197010). 
Plates were read each hour for 5 hours at 495 nm. Absorbance values were converted to 
percent viability, using the no-drug control as 100% viability. These values were then plotted 
against concentration and fit with a non-linear regression using GraphPad Prism. 
 
Scratch Cell Migration Assay 
Migration of B16F10 cells in response to AvFc was measured using a scratch cell 
migration assay, also called a wound-healing assay. B16F10 cells were grown on a 6-well plate 
until confluency, at which point they were serum starved for 6-8 hours. After starvation, each 
well was scratched twice using a pipette tip and washed with PBS to remove floating cells. Each 
well was then filled with serum-free media containing AvFc at 0.12, 0.6, or 3 μM or AvFclec- at 3 
μM. One well was used as a no-drug control. Two lines perpendicular to the scratches were 
made in each well to give a reference point when imaging the scratches. An inverted fluorescent 
microscope was used to image the scratches at 0, 17, 41, and 64 hours. The area of the scratch 
was then calculated using ImageJ, and percentage of area closed was calculated and plotted 
against time.  
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Pharmacokinetics of AvFc in C57bl/6 Mice 
 The pharmacokinetics of AvFc in mice was evaluated using 4 groups of 4 mice each, per 
gender. At time 0, all animals were given a 25 mg/kg dose of AvFc intraperitoneally. Blood was 
sampled at two time points per group of 4 mice (0.5 and 8 hours, 1 and 24 hours, 2 and 48 
hours, and 4 and 72 hours), using the submandibular vein for the first small draw and 
euthanasia/cardiac puncture for the second. Serum was then assayed for AvFc using a gp120 
ELISA, which had been validated in the presence of mouse serum (no major matrix effects were 
detected). Serum concentration was plotted against time, and PK parameters were estimated 
using PK Solver [74]. 
 
A549-GFP Lung Cancer Model 
The A549-GFP lung cancer model was carried out using 20 NOD.CB17-Prkdcscid/J (or 
NOD-SCID) or 20 B6.CB17-Prkdcscid/SzJ (or SCID) mice. A549-GFP cells were grown in DMEM with 
10% FBS. On day 0, animals were split evenly into groups of 10 and given either vehicle or AvFc 
at 25 mg/kg intraperitoneally. After 2-4 hours, 2 x 106 A549-GFP cells were injected 
intravenously. Dosing continued every other day for a total of six doses. After 28 days animals 
were euthanized, and their lungs imaged with a fluorescence-capable camera. Fluorescence was 
quantified using ImageJ, and any gray value under 100 was considered to be background.  
 
Experimental Animals 
All animal work was conducted with approval by the University of Louisville Institutional 
Animal Care and Use Committee and in concordance with its policies. All animals were housed in 
dedicated facilities with free access to food and water and acclimatized to the environment for 1 
week prior to beginning any study. Animals were routinely monitored for health, and euthanasia 
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performed when human endpoints were met or at the conclusion of the study. Asphyxiation 
with CO2 was used as the primary method of euthanasia, followed by cervical dislocation as an 
adjunct method.  
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CHAPTER III: RESULTS 
Anti-SIV Activity of AvFc 
The anti-SIV activity of AvFc was first explored using an in vitro neutralization assay. 
Three highly pathogenic strains of SIV were donated from Dr. Francois Villinger’s group at the 
New Iberia Research Center at the University of Louisiana, Lafayette: smE660, isolated from the 
African sooty mangabey, and mac239 and mac251, which were isolated from macaques. These 
strains were chosen as they are commonly used in HIV/SIV vaccine studies and in macaque 
challenge models as they are capable of establishing a disease similar to AIDS in monkeys. AvFc 
was capable of neutralizing all three strains of the virus (Figure 7) with IC50 values of 15.3 nM 
(smE660), 6.6 nM (mac239), and 1.8 nM (mac251).  These values are comparable to though 
slightly higher than the average IC50 obtained against primary HIV strains using PBMCs as the 
target cell (0.3 nM; Hamorsky, Kouokam, Dent et al. submitted). Conversely, AvFclec- was 
incapable of neutralizing the virus, indicating that neutralization occurred due to the binding of 




Figure 7 - SIV Neutralization by AvFc. Neutralization of primary SIV was measured as a decrease 
in luminescent signal in a TZM-bl assay. AvFc was capable of neutralizing SIV smE660, mac239, 
and mac251 with IC50 values in the low nanomolar range (15.3, 6.6, and 3.8 nM respectively). 
Conversely, AvFclec- was incapable of neutralizing the virus. A representative curve for the 3 
strains and for the negative control are shown above. 
 
Next, flow cytometry was used to determine whether or not AvFc could recognize SIV-
infected cells. Cells isolated from macaque MLNs were infected with SIVmac251 and stained with 
AvFc and a goat anti-human IgG-FITC. As shown in Figure 8, AvFc bound and recognized infected 
cells at concentrations of 1 and 10 μg/mL. However, it was not able to bind to uninfected cells at 
10 μg/mL, indicating that AvFc is specific for HMGs displayed on the surface of the infected cells. 
Being able to bind infected cells is necessary for the induction of ADCC and may improve the 
efficacy of AvFc in in vivo SIV-challenge models. To prepare for such a model, it was necessary to 
understand the pharmacokinetics of AvFc in a macaque so that an appropriate dosing regimen 
could be decided. Two female macaques were given a 21 mg intravenous bolus dose of AvFc 
(3.6 and 3.7 mg/kg), and serum was sampled at 0, 0.5, 1, 2, 4, 8, 24, 48, and 72 hours. Before 
serum could be assayed for AvFc by gp120 ELISA, we first had to determine whether or not 
macaque serum would interfere with its binding to gp120. A gp120 ELISA using varying 
concentrations of macaque serum from a commercial vendor spiked with AvFc showed no 
change in EC50, LLOD, or LLOQ (Figure 9), indicating that there was no matrix effect on detection. 
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AvFc was detected in all macaque serum samples, except for time 0, and the resulting 
concentration vs. time curve indicated that AvFc has a half-life in macaques of 27.6 ± 3.5 hours, 
and a clearance rate of 7.8 ± 3.2 mL/hour. Other PK parameters can be seen in Figure 10. For a 
25 mg/kg dose (considered to be a “high” dose for our purposes) in an average macaque (5.34 
kg, 325 mL blood volume), AvFc would need to be dosed every 6 days to maintain a blood 
concentration of 130 nM, or roughly 10 μg/mL, which is the target concentration for SIV 
neutralization in vivo.  
 
Figure 8 - Recognition of SIV-infected Macaque MLN cells by AvFc. SIV-infected macaque MLN 
cells were stained with AvFc and analyzed by flow cytometry. AvFc was able to detect infected 
cells at concentrations of 1 and 10 μg/mL, while conversely no positive signal was seen with 




SERUM (%) EC50 (nM) LLOD (nM) LLOQ (nM) 
0 0.125 0.011 0.029 
20 0.127 0.013 0.031 
40 0.083 0.009 0.021 
60 0.088 0.009 0.022 
80 0.085 0.013 0.027 
100 0.091 0.008 0.021 
 
Figure 9 - Matrix Interference by Macaque Serum in the gp120 ELISA. A standard gp120 ELISA 
was performed by spiking AvFc into varying concentrations of macaque serum. No significant 
change in EC50, LLOD, or LLOQ was seen, indicating that the inclusion of serum would not 












Parameter Unit Value Parameter Unit Value 
Lambda z 1/h 0.0223 Lambda z 1/h 0.0287 
t1/2 h 31.1 t1/2 h 24.2 
tmax h 2 tmax h 1 
Cmax μg/ml 100.93 Cmax μg/ml 275.94 
C0 μg/ml 69.36 C0 μg/ml 159.38 
Clast/Cmax 
 
0.0843 Clast/Cmax  0.0513 
AUC0-t μg/ml*h 1523.7 AUC0-t μg/ml*h 4036.3 
AUC0-∞ μg/ml*h 1905.3 AUC0-∞ μg/ml*h 4529.8 
AUC0-t/0-∞ 
 
0.7997 AUC0-t/0-∞  0.8911 
AUMC0-∞ μg/ml*h^2 76152.3 AUMC0-∞ μg/ml*h^2 135017.2 
MRT 0-∞ h 39.97 MRT 0-∞ h 29.81 
Vz (mg)/(μg/ml) 0.4942 Vz (mg)/(μg/ml) 0.1616 
CL (mg)/(μg/ml)/h 0.01102 CL (mg)/(μg/ml)/h 0.00464 
Vss (mg)/(μg/ml) 0.44052 Vss (mg)/(μg/ml) 0.13818 
 
Figure 10 - Pharmacokinetic Analysis of AvFc in Rhesus Macaques. Top, the concentration vs. 
time curve of AvFc in macaque serum after a single intravenous bolus dose of 21 mg of AvFc. 
The dotted line indicates 130 nM, or 10 μg/mL, the goal concentration for SIV neutralization in 
vivo (at least 10x the IC50). The bottom tables show the PK parameter output from the PK Solver 
software, which gives an average half-life of about 27.7 hours.  
 
Anti-HCV Activity of AvFc 
The anti-HCVcc activity of AvFc was evaluated in an immunofluorescence assay using 
replication-permissive Huh7.5 cells and replication competent J6/JFH-1 virus (genotype 2a). 
AvFc was capable of neutralizing the virus with an IC50 value of 2.4 nM, a potency similar to what 
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Figure 11 - HCV Neutralization by AvFc. Neutralization of HCV by AvFc was measured as a 
reduction in infectious foci in an immunofluorescence assay using Huh7.5 cells as the target cell.  
AvFc was able to neutralize the virus with an IC50 of 2.4 nM, similar to values obtained against 
SIV and HIV.  
 
Anti-Cancer Activity of AvFc 
It has previously been demonstrated that AvFc is capable of binding to a number of 
cancer-cell lines and inducing ADCC, owing to the expression of HMGs on the surface of many 
types of cancer (Figure 6). To expand on this, we used the B16F10 mouse melanoma lung 
metastasis model to determine whether or not the protein has any in vivo efficacy. First, 
however, we had to determine whether or not it was capable of recognizing the cell line. The 
binding to B16F10 cells was evaluated using flow cytometry, which showed over 80% of cells 
being bound at 130 nM and 50% at 20.3 nM (Figure 12). Binding to B16F10 cells also allowed for 
the induction of ADCC, demonstrated using an FcγRIIIa-luc-expressing Jurkat reporter cell line, 
with an EC50 of 1.51 nM (Figure 13). At the highest concentrations tested, AvFc elicited 
approximately a 4-fold increase in luciferase expression. The ability of the drug to bind and elicit 
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ADCC justified the further use of AvFc in the B16F10 melanoma lung metastasis model, which 
would demonstrate any in vivo activity.  
 
 
Figure 12 - Binding of AvFc to B16F10. The binding of AvFc to B16F10 mouse melanoma cells 
was evaluated using flow cytometry and a single-color FITC stain. Live cells were gated from the 
100,000 total cells that were counted (left panel). The PBS-only control was then used to gate 
for FITC+ cells. At the highest concentration tested (130 nM), AvFc bound to approximately 80% 
of the cells. The EC50 of AvFc binding was determined to be 20.3 nM, calculated by non-linear 




Figure 13 - ADCC Activity of AvFc Against B16F10 Cells. B16F10 cells, plated in a 96-well plate, 
were incubated with AvFc and a reporter cell line which expresses luciferase upon engagement 
of FcγRIIIa, which is the primary receptor responsible for inducing ADCC. As shown above, AvFc 
is capable of inducing ADCC in a dose-dependent manner with an EC50 value of 1.51 nM. The 
mutant AvFclec-, which cannot bind HMGs, was incapable of inducing ADCC. 
 
In this model, 2.5 x 105 B16F10 cells were injected IV and AvFc, a non-sugar-binding 
mutant AvFclec-, or a vehicle was administered to mice concurrently and every other day 
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afterwards for a total of 6 doses. No significant changes in body weight or behavior were seen in 
any of the treatment groups, indicating that the drug was well tolerated with little acute toxicity 
(data not shown). On day 21, lungs isolated from the treated mice displayed significantly fewer 
nodules than the vehicle control (Figure 14). Furthermore, lungs isolated from the AvFclec- group 
did not show such a decrease, indicating that AvFc specifically was responsible for the anti-
cancer activity seen. When treatment was delayed however, the results were less clear. 
Treatment of mice 7 days after IV injection of B16F10 cells did appear to improve mouse survival 
slightly, but non-significantly (Figure 15). Likewise, using a B16F10 flank tumor model, in which 
2.5x105 cells were injected into the hind-left flank of the animal and treatment was delayed until 
the tumors became visible, a significant delay in tumor growth by day 14 was seen (Figure 16). 




Figure 14 - B16F10 Melanoma Metastasis Model, Co-treatment with AvFc. On day 0, 250,000 
B16F10 cells were injected IV into 8-10 week old C57bl/6 mice. The treatment was begun the 
same day as the cells were administered and continued every other day for a total of 6 doses. 
On day 21, lungs were isolated and the number of tumor nodules counted. While the mutant, 
non-HMG-binding AvFclec- was unable to prevent the formation of tumors in the lung, AvFc at 
the same dose significantly reduced the number of lung nodules. Data were analyzed by 1-way 




Figure 15 - B16F10 Melanoma Metastasis Model, Delayed Treatment with AvFc. Using the 
same melanoma metastasis model as in Figure 14, but by delaying treatment for 7 days, we 
found that AvFc did not significantly improve the survival of C57bl/6 mice (p=0.1550, Gehan-
Breslow-Wilcoxon test). However, there was a trend towards increased survival which may be 
resolved with a larger sample size or more optimal dosing regimen. No differences in the lung 
nodules were noted.  
 
 
Figure 16 - B16F10 Flank Tumor Model with Delayed Treatment. In this model, mice were given 
250,000 B16F10 cells in the hind left flank subcutaneously and dosed with AvFc beginning when 
the tumors became visible (day 5). Dosing continued every other day until day 14. A delay in 
tumor growth was noted and a significant decrease in average tumor volume was seen 
beginning on day 12. Data were analyzed by 2-way ANOVA with multiple comparisons corrected 
using Tukey’s range test.  
 
A number of experiments were then conducted to elucidate the possible anti-cancer 
mechanism of AvFc. One possibility is that AvFc targets a specific receptor or receptors, resulting 
in anti-cancer activity. Co-immunoprecipitation of A549, H460 (lung cancers), HL-60, and K562 
(blood cancers) cell lysates with AvFc or the mutant AvFclec- led to the identification of several 
surface markers that may be targeted by the drug (Table 1). EGFR, SORL1, IGF1R, LRP1, 
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CNTNAP1, and LRP10 were all identified in both of the lung cancer cell lines. EGFR is the target 
of several approved monoclonal antibody immunotherapies for lung cancer, including 
cetuximab. IGF1R on the other hand, is the target of several experimental antibody 
immunotherapies, though none have been approved to date [75-78]. Thus, it is possible that 
part of AvFc’s mechanism may be due to the targeting of these receptors, and indeed data 
produced in our laboratory (not shown) seems to agree with this. Common between the two 
blood cancers was LAMP1 and ICAM1. Adhesion molecules like ICAM1 may play a role in cell 
metastasis and malignancy, and so it is hypothetically possible that AvFc may interact with these 
kinds of molecules to affect cancer-cell movement [79]. Lastly, a number of receptors were 
found to be common to all four of the cell-lines tested, including IGF2R, PLXNB2, NPC1, and 
M6PR. Particularly, IGF2R and M6PR are known to be mutated in some cancer types [80]. Based 
on these results, it seems possible that AvFc may be targeting some specific receptors on the 
cell surface to elicit its anti-cancer activity. 
Found in both lung cancer cell-lines 
Gene Name Accession 
Molecular 
Weight 
Cluster of Epidermal growth factor receptor 
GN=EGFR  
sp|P00533|EGFR_HUMAN 134 kDa 
Cluster of Sortilin-related receptor GN=SORL1  sp|Q92673|SORL_HUMAN 248 kDa 
Cluster of Insulin-like growth factor 1 receptor 
GN=IGF1R  
sp|P08069|IGF1R_HUMAN 155 kDa 
Prolow-density lipoprotein receptor-related 
protein 1 GN=LRP1  
sp|Q07954|LRP1_HUMAN 505 kDa 
Contactin-associated protein 1 GN=CNTNAP1  sp|P78357|CNTP1_HUMAN 156 kDa 
Low-density lipoprotein receptor-related 
protein 10 GN=LRP10  
sp|Q7Z4F1|LRP10_HUMAN 76 kDa 
Found in both blood cancer cell-lines 
Gene Name Accession 
Molecular 
Weight 
Lysosome-associated membrane glycoprotein 
1 OS=Homo sapiens GN=LAMP1  
sp|P11279|LAMP1_HUMAN 45 kDa 
Intercellular adhesion molecule 1 GN=ICAM1  sp|P05362|ICAM1_HUMAN 58 kDa 
Found in all four cancer cell-lines 
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receptor GN=IGF2R  sp|P11717|MPRI_HUMAN 274 kDa 
Plexin-B2 GN=PLXNB2  sp|O15031|PLXB2_HUMAN 205 kDa 
Niemann-Pick C1 protein GN=NPC1  sp|O15118|NPC1_HUMAN 142 kDa 
Cation-dependent mannose-6-phosphate 
receptor GN=M6PR  sp|P20645|MPRD_HUMAN 31 kDa 
Integrin alpha-5 GN=ITGA5  sp|P08648|ITA5_HUMAN 115 kDa 
Table 1 - Identification of the Cell-surface Binding Partners of AvFc. Co-immunoprecipitation 
was performed with AvFc or a negative control, AvFclec-, on cancer-cell lysates from 4 cell lines: 
A549, H460, HL-60, and K562. Proteins were then identified using mass spectrometry. Those 
that were identified both in the negative control samples and in the AvFc samples were 
removed from the final analysis, as were any proteins identified that were not integral plasma 
membrane proteins (as determined by gene ontology keywords and literature search). The most 
immediately interesting binding partners identified were EGFR, IGFR1, and IGFR2, which are 
known to be upregulated or improperly functioning in many cancers. AvFc was also found to 
bind a number of adhesion molecules and transporters.  
 
 
To explore the non-Fc-mediated anti-cancer activity of the drug, the viability of B16F10 
cells and their ability to migrate in the presence of AvFc was then explored using MTS and 
scratch cell-migration assays. In the MTS assay, AvFc only showed cytotoxicity at the highest 
concentrations tested (0.6 and 3 μM), with an EC50 value of 9.7 μM (Figure 17). At similar 
concentrations however, no anti-migratory effect was seen in the cell-migration assay (Figure 
18). This seems to indicate that, at least with the cell lines and concentrations tested, that AvFc 
has little innate anti-cancer activity arising simply from the Avaren portion binding to its target. 
Furthermore, based on a pharmacokinetic study of AvFc in C57bl/6 mice it would be unlikely 
that the protein reached such high concentrations in the blood of mice in the B16F10 challenge 
studies. A single 25 mg/kg dose of AvFc showed a peak blood concentration of about 2.5 μM in 
males and 1.9 μM in females, far lower than even the EC50 of the drug in the MTS assay. It may 
be possible to increase Cmax by dosing every day, given that the half-life of the drug was 
determined to be 25.4 hours in males and 18.5 hours in females (Figure 19).  
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Figure 17 - Effect of AvFc Exposure on B16F10 Viability. Varying concentrations  of AvFc were 
added to 5,000 B16F10 cells on a 96-well plate beginning at 3 μM. Cells were exposed to AvFc 
for 48 hours, at which point the MTS reagent was added to the wells and incubated for 3 hours 
at 37°C. While AvFclec- was unable to elicit any cytotoxicity at any concentration, AvFc showed 
moderate cytotoxicity at the highest concentrations with an estimated EC50 of 9.7 μM.  
 
 
Figure 18 - Migration of AvFc-exposed B16F10 cells. The migration of B16F10 cells during 
exposure to varying concentrations of AvFc was evaluated by a scratch assay on a 6 well plate. 






Parameter Unit Value Parameter Unit Value 
Lambda z 1/h 0.0273 Lambda z 1/h 0.037 
t1/2 h 25.4 t1/2 h 18.5 
tmax h 2 tmax h 4 
Cmax nmol/L 2507.667 Cmax nmol/L 1886.4 
Clast_obs/Cmax 
 
0.0989 Clast_obs/Cmax  0.0647 
AUC0-t nmol/L*h 23083.6 AUC0-t nmol/L*h 24967.3 
AUC0-∞ nmol/L*h 32164.7 AUC0-∞ nmol/L*h 28226.6 
AUC0-t/0-∞ 
 
0.718 AUC0-t/0-∞  0.885 
AUMC0-∞ nmol/L*h^2 1208450.5 AUMC0-∞ nmol/L*h^2 564592.6 
MRT0-∞ h 37.57 MRT0-∞ h 20.00 
Vz/Fobs (μg)/(nmol/L) 0.569 Vz/Fobs (μg)/(nmol/L) 0.473 
Cl/Fobs (μg)/(nmol/L)/h 0.0155 Cl/Fobs (μg)/(nmol/L)/h 0.0177 
 
Figure 19 - Pharmacokinetics of AvFc in C57bl/6 Mice. Top, the concentration vs. time curve of 
AvFc in C57bl/6 serum after a single intraperitoneal dose of 500 μg. The two dotted lines 
represent the EC90 of AvFc’s ADCC activity against B16F10 cells and that value times 100, which 
we use as the target concentration that we wish to maintain in the blood. To achieve this 
concentration, a 500 μg dose of AvFc should be given every 48 hours or so. The bottom tables 
show the PK parameter output from the PK Solver software, with the average half-life estimated 
as approximately 22 hours. Based on the Cmax, the average weight of a 10-week old C57bl/6 
mouse (25.6 for males, 19.8 for females) and the average blood volume (79 mL/kg), the 
bioavailability was calculated as 78% for males and 45% for females. 
 
To demonstrate the necessity of AvFc’s Fc effector functions to its anti-cancer activity, 
an A549-GFP lung cancer model was employed using two strains of immunocompromised mice: 
NOD.CB17-Prkdcscid/J (or NOD-SCID) and B6.CB17-Prkdcscid/SzJ (or SCID) (Figure 20). These cells 
stably and constitutively express GFP, allowing for their detection ex-vivo. With co-treatment 
with AvFc, no significant decrease in lung GFP intensity was seen in the NOD-SCID mice, which 
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lack B, T, and functional NK cells. However, a significant decrease was seen in the SCID mice, 
which lack B and T cells but retain NK cells. Since NK cells are the primary effector cells for ADCC, 
it appears that their presence is necessary for AvFc to exert its anti-cancer activity at least in this 
particular model. 
  
Figure 20 - A549-GFP Lung Cancer Model, Co-treatment with AvFc. In this model, mice were 
given 2x106 A549-GFP cells and co-treated with AvFc at 25 mg/kg beginning on day 0 and 
continuing every other day for six doses. On day 28, animals were euthanized and the GFP 
intensity in the lungs quantified by fluorescent imaging and ImageJ. The same model was done 
in SCID and NOD-SCID mice. In NOD-SCID mice, AvFc did not show any efficacy, though it did in 
SCID mice, indicating that Fc functions are important for AvFc’s mechanism. 
47 
CHAPTER IV: DISCUSSION 
It is becoming clear that aberrant glycosylation brought on by certain viruses and cancer 
may be a useful biomarker or pharmaceutical target, and the goal of this work was to 
demonstrate that targeting HMGs with a specific carbohydrate-binding-agent (CBA) is a possible 
therapeutic approach. To date, there are only a handful of CBAs in clinical development and one 
approved drug – dinutuximab – which is an anti-GD2 disialoganglioside mAb for the treatment 
of certain high-risk pediatric neuroblastomas [81]. Even fewer agents are capable of binding 
specifically to disease-associated HMGs. For example, HMGs from gp120 make up a significant 
portion of the epitope of the HIV bNAb 2G12 [82], though the remainder of it is formed by the 
underlying protein limiting the bNAbs activity to HIV-1. Another antibody, TM10, was found to 
bind much more specifically to HMGs and was even capable of recognizing multiple cancer cell-
lines [83]. However, there was little in vivo efficacy largely due to the fact that the antibody is an 
M class immunoglobulin, which primarily remains in the vasculature and has little to no effector 
function. A potential solution to the above limitations may be the development of a novel CBA 
that can target HMGs specifically and make use of Fc-mediated effector functions. This makes 
AvFc a first in class molecule which may be well suited for this purpose, owing to its high 
specificity for HMGs and HMG-bearing viruses and cancer cells and its inclusion of the Fc region 
of human IgG1 which allows for efficient induction of effector functions. 
As demonstrated in this work, AvFc can neutralize SIV and HCV, owing to the fact that 
the envelope proteins of these viruses contain dense arrays of HMGs on their surface. 
SIVmac239, for example, contains 27 sites while the E1 and E2 proteins of HCV contain 15, 
48 
which cover their surfaces and serve as a glycan shield hiding the underlying protein structure 
from the immune system. AvFc appears to have little to no affinity for either the disaccharide 
α1,2-mannobiose or the glycan Man9 individually (data not shown). Instead, it appears that 
AvFc requires not only the presence of these glycans but requires a certain density of them so as 
to engage all three of the sugar binding sites at once, as has been demonstrated for the parent 
lectin actinohivin [cite Tanaka et al PNAS paper]. Additionally, AvFc may interact with multiple 
glycans on the surface of the virus with being specific to any particular one, the implication of 
this being that AvFc could neutralize any virus that displays a high number of HMGs. This 
however is not the case. Viruses such as Middle East respiratory syndrome coronavirus (MERS-
CoV) or Ebola, both of which have HMG-rich glycoproteins that AvFc can indeed bind to 
(measured by Biacore, not shown), are nonetheless resistant to neutralization by it. Thus, it 
seems that it is not just the presence or absence of HMGs that determines whether or not AvFc 
can bind and neutralize a virus but rather it is the spatial arrangement of those glycans on the 
viral surface in the context of virus-host interaction; these glycans must be located on or near 
integral entry or fusion domains so as to block their action during infection. What remains to be 
explored is where exactly on HIV gp120 or HCV E1/E2 AvFc is binding to that allows it to 
neutralize those viruses, and not others with similar properties.  
The primary barrier to an HIV cure is the presence of latent viral reservoirs, which 
harbor proviral DNA in the host cell chromosome that do not express antigen and are not 
eliminated by antiretroviral therapy. Much work has been done to identify agents that can 
reactivate the virus and allow for the recognition and elimination of infected cells (latency 
reversal agents, LRAs), with the major candidates belonging to the group of histone deacetylase 
inhibitors like romidepsin [84]. No single LRA has been identified that can decrease the size of 
the viral reservoir, thus it is likely that a combination therapy consisting of an LRA and a bNAb is 
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necessary for effective treatment [64]. In order for this to be effective, the bNAb must be able to 
recognize infected cells and effectively elicit ADCC. To date, few descriptions of antibodies that 
are capable of this have been published [65, 85-87]. As demonstrated in this work, AvFc can 
effectively recognize SIV-infected MLN cells isolated from rhesus macaques (Figure 8), opening 
up the possibility that any SIV-infected cells can be targeted and possibly eliminated through 
ADCC in vivo in combination with an LRA. Further studies are needed to assess the effects of 
AvFc on the latent reservoir.  
The present study demonstrated that AvFc has anti-cancer activity in multiple models 
though the exact mechanism is not known. Unlike contemporary cancer immunotherapies like 
cetuximab, AvFc does not have a single protein target on the surface of the cell and, based on 
co-immunoprecipitation data, may interact with a number of surface receptors, adhesion 
molecules, and transporters that display HMGs (Table 1). Despite effective binding to cancer 
cells, AvFc does not seem to be cytotoxic or disrupt cell migration except at very high 
concentrations (> 1 μM, Figure 17, Figure 18).  This would seem to imply that Fc-mediated 
effector functions, and not direct cell inhibition, are necessary for its anti-cancer activity. This 
hypothesis is supported by the fact that little activity is seen in the A549 cancer model only in 
SCID mice and not in NOD-SCID mice, which are deficient in NK cells and other innate cells 
(Figure 20). Further studies are warranted to confirm the hypothesis and to refine the Fc-
mediated antitumor activity of AvFc, particularly through the use of variants of AvFc with 
modified Fc regions. Changes to the amino acid sequence or to the glycan profile of the Fc 
region can increase or decrease its affinity to the various FcγRs. One well-characterized Fc 
mutant is GASDALIE (G236A/S239D/A330L/I332E), which increases the affinity of antibodies to 
FcγRI and FcγRIIIa. This mutation has been shown to increase the protection conferred by 
monoclonal antibodies in mouse models of cancer and infectious disease [88-90]. Removal of 
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the core fucose in the glycan located at the single N-glycosylation site in the CH2 domain of the 
Fc region also increases the affinity for FcγRIIIa and allows for a stronger elicitation of ADCC [91]. 
Conversely, mutation of the abrogates binding to FcγRs and limits ADCC activity [92]. Further 
studies with AvFc should incorporate these mutants to demonstrate whether or not AvFc’s 
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